ECOG-ACRIN logoECOG-ACRIN logoECOG-ACRIN logoECOG-ACRIN logo
  • Home
  • Archives
  • Contact
✕
  • Filter by
  • Categories
  • Tags
  • Authors
  • Show all
  • All
  • Advocacy
  • Anal cancer
  • Artificial intelligence (AI)
  • Bladder cancer
  • Brain cancer
  • Breast cancer
  • Colorectal cancer
  • ComboMATCH
  • Esophagus cancer
  • Gallbladder cancer
  • Head and neck cancer
  • Health equity
  • Immunotherapy
  • In memory
  • Kidney cancer
  • Leukemia
  • Liver cancer
  • Lung cancer
  • Lymphoma
  • Mammography
  • Melanoma
  • Myelodysplastic syndrome
  • Myeloma
  • NCI-MATCH
  • Older adults
  • Pancreatic cancer
  • Pancreatic cysts
  • Patient education
  • Patient navigation
  • Patient-reported outcomes
  • Penis cancer
  • Personalized treatment
  • Policy
  • Precision medicine
  • Prevention
  • Prostate cancer
  • Real-world data/evidence
  • Research results
  • Sarcoma
  • Screening for cancer
  • Side effects
  • Survivorship
  • Targeted therapy
  • Upper tract urothelial cancer
  • Young adults
May 19, 2025
May 19, 2025
Categories
  • New Trials

Now Enrolling: The PTCL-STAT research study is testing the use of stem cell transplants for patients with an aggressive type of lymphoma

This study is for patients who are in remission after their initial treatment for peripheral T-cell lymphoma
Do you like it?
0 Read more
May 19, 2025
May 19, 2025
Categories
  • Ongoing Trials

Ongoing Trials: A closer look at ECOG-ACRIN’s studies for patients with head and neck cancer

These four actively recruiting clinical trials are exploring possible new treatment approaches
Do you like it?
0 Read more
May 19, 2025
Research dictionary entry
May 19, 2025
Categories
  • Trial Results

Top trial results of 2024: A year of major progress in cancer treatment

Seven ground-breaking findings from cancer clinical trials in 2024 by ECOG-ACRIN and PrECOG
Do you like it?
0 Read more
January 16, 2025
January 16, 2025
Categories
  • Editorials

Real-world data 101: An overview

Real-world data and real-world evidence are important when it comes to cancer research because they can complement and expand findings from randomized clinical trials
Do you like it?
0 Read more
Prev page
123456789101112131415161718
Next page

News, editorials, and perspectives for the cancer research advocacy community

✕

Categories

  • Editorials
  • New Trials
  • Ongoing Trials
  • Trial Results

Resources

  • Active ECOG-ACRIN Trials
  • Advocacy Organizations
  • Myths and Facts
STAY UP TO DATE

Subscribe to receive updates from the ECOG-ACRIN advocacy committee.

Select list(s) to subscribe to


Office of Communications
1818 Market Street, Suite 3000
Philadelphia, PA 19103
Phone: 215.789.3631
www.ecog-acrin.org

Contact us with any questions

© 2019-2026 ECOG-ACRIN Cancer Research Group. All Rights Reserved. Designed by Create & Associates, Inc